Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 26;73(3):428-34.
doi: 10.1021/np900638e.

Synthesis of 7-(15)N-Oroidin and evaluation of utility for biosynthetic studies of pyrrole-imidazole alkaloids by microscale (1)H-(15)N HSQC and FTMS

Affiliations

Synthesis of 7-(15)N-Oroidin and evaluation of utility for biosynthetic studies of pyrrole-imidazole alkaloids by microscale (1)H-(15)N HSQC and FTMS

Yong-Gang Wang et al. J Nat Prod. .

Abstract

Numerous marine-derived pyrrole-imidazole alkaloids (PIAs), ostensibly derived from the simple precursor oroidin, 1a, have been reported and have garnered intense synthetic interest due to their complex structures and in some cases biological activity; however very little is known regarding their biosynthesis. We describe a concise synthesis of 7-(15)N-oroidin (1d) from urocanic acid and a direct method for measurement of (15)N incorporation by pulse labeling and analysis by 1D (1)H-(15)N HSQC NMR and FTMS. Using a mock pulse labeling experiment, we estimate the limit of detection (LOD) for incorporation of newly biosynthesized PIA by 1D (1)H-(15)N HSQC to be 0.96 microg equivalent of (15)N-oroidin (2.4 nmole) in a background of 1500 microg of unlabeled oroidin (about 1 part per 1600). 7-(15)N-Oroidin will find utility in biosynthetic feeding experiments with live sponges to provide direct information to clarify the pathways leading to more complex pyrrole-imidazole alkaloids.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Oroidin (1a) and other representatives of the pyrrole-imidazole alkaloid (PIA) family from marine sponges.
Figure 2
Figure 2
MALDI FTMS (7T) expansions of the pseudomolecular ion [M+H]+ of oroidin for (a) natural 1a (C11H12Br214N5NO) and (b) 7-15N-oroidin (1d), C11H12Br2Br214N415NO, >98% atom 15N. Mass accuracy = 1ppm.
Figure 3
Figure 3
MALDI FTMS (7T) expansions of m/z and peak height, h, for the ‘M+1’ peak of the pseudomolecular ions of oroidin (C11H11Br2N5O). Mass accuracy = 1 ppm (R = 240,000). (a) natural 1a. (b) 1a + 1d (0.04 mol equiv). (c) 1a + 1d (0.10 mol equiv). Peak assignments of [M+H]+ in (c): m/z 388.94372, 12C1013CH12Br2N5O+; m/z 388.93739; 12C11H12Br2N415NO+. The unrelated peak at m/z 388.9305 (indicated with an ‘*’) is tentatively assigned to some loss of H from the dominant 79Br/81Br isotopomer, C11H1079Br81BrN5O+ ([M]+, Δmmu = –0.5).
Figure 4
Figure 4
2D 1H-15N HSQC (600 MHz, 1:1 DMSO-d6/benzene-d6) of natural oroidin (1a, depicted tautomer is arbitrary). N locants are labeled following the numbering scheme of Assman and Köck (Ref.xxxii). ns = 16, T2, T1 = 2K × 256; F2, F1 = 2K × 1K; d1 =1.5s
Figure 5
Figure 5
1D 1H-15N HSQC experiments (1H δ, 1.7 mm microcryoprobe, 600 MHz) of 1a with N-H assignments. Labels indicate N atom assignments made from a separate 1H-15N HMBC experiment (not shown). (a) 1500 μg of 1a, no added [15N]-1d. (b) 1500 μg 1a + 10 μg 1d. (c) 1500 μg 1a + 5.0 μg 1d. (d) 1500 μg 1a + 2.5 μg. Relaxation delay, d1 = 1.50 s, optimized for 1JN-H = 90 Hz; 1H π/2 pulse = 12 μS, 15N π/2 pulse = 34 μS; NA = 6K; dummy scans = 16; NI = 1; T2 = F2= 8K points (no zero fill). See Supporting Information for calculations of limit of detection (LOD), mean and SD.
Figure 6
Figure 6
Linear regression of 1H-15N HSQC cross-peak integral ratio, (II0)/I0 for the NH(C=O) signal in ‘mock’ pulse labeling experiments with natural abundance 1a (1500 μg, I0) spiked with measured aliquots of 1d (μg, ‘x-scale'). Observed values, I, for the NH-C=O 1H-15N couplet are normalized to the intensity of Ipy the pyrrole N-H cross peak. For the NH(C=O) peak in the natural abundance sample (no added 1d), I = I0 and I0/Ipy = 1.00. Error bars are ± SD.
Figure 7
Figure 7
Possible biosynthesis of oroidin (1a) and conversion to stevensine (17)
Scheme 1
Scheme 1
Retrosynthetic analysis of 7-15N-oroidin (1d) from urocanic acid.
Scheme 2
Scheme 2
Synthesis of 15N-labeled oroidin.a aReagents and conditions: (a) AcCl, MeOH, reflux, quant.; (b) TrCl, Et3N, DMF; (c) DIBAL-H, THF; (d) TBSCl, imidazole, 74% for 3 steps; (e) n-BuLi, TsN3, THF, 94%; (f) TBAF, THF, 82%; (g) MsCl, Et3N, THF; (h) potassium phthalimide-15N, DMF, 42% for 2 steps; (i) NH2NH2, EtOH, 50 °C; (j) 4,5-dibromo-2-trichloroacetylpyrrole, Na2CO3, DMF, 76% for 2 steps; (k) AcCl, MeOH/EtOAc, 99%; (l) H2/Pd-Lindlar, MeOH/THF, 84%.

Similar articles

Cited by

References

    1. Recent examples of syntheses of pyrrole-imidazole alkaloids: Arndt H-D, Koert U. In: Organic Synthesis Highlights 4. Schmalz H-G, editor. Wiley-VCH; Weinheim: 2000. p. 241.; Hoffmann H, Lindel T. Synthesis. 2003:1753–1783.; Jacquot DEN, Lindel T. Curr. Org. Chem. 2005;9:1551–1565.; Du H, He Y, Sivappa R, Lovely C. J. Synlett. 2006:965–992.; Kock M, Grube A, Seiple IB, Baran PS. Angew. Chem. 2007;119:6706–6714.; Angew. Chem. Int. Ed. 2007;46:6586–6594.; Weinreb SM. Nat. Prod. Rep. 2007;24:931–948.; For some publications not covered in the these reviews, see: Dransfield PJ, Dilley AS, Wang S, Romo D. Tetrahedron. 2006;62:5223–5247.; Wang S, Dilley AS, Poullennec KG, Romo D. Tetrahedron. 2006;62:7155–7161.; Nakadai M, Harran PG. Tetrahedron Lett. 2006;47:3933–3935.; Tan X, Chen C. Angew. Chem., Int. Ed. 2006;45:4345–4348.; Overman LE, Paulini R, White NS. J. Am. Chem. Soc. 2007;129:12896–2900.; O'Malley D, Yamaguchi J, Young IS, Seiple IB, Baran PS. Angew. Chem. Int. Ed. 2008;47:3581–3583. ; Yamaguchi J, Seiple IB, Young IS, O'Malley DP, Maue M, Baran PS. Angew. Chem. Int. Ed. 2008;47:3578–3580.; Bhandari MR, Sivappa R, Lovely CJ. Org. Lett. 2009;11:1535–1538.

    1. Al Mourabit A, Potier P. Eur. J. Org. Chem. 2001:237–243.
    1. Walker RP, Faulkner DJ, VanEngen D, Clardy J. J. Am. Chem. Soc. 1981;103:6772–6773. An variation on the sceptrin skeleton, embodying an unusual benzocyclobutane (benzosceptrins A and B), has just been reported. Appenzeller J, Tilvi S, Martin M-T, Gallard J-F, El-bitar H, Dau ETH, Debitus C, Laurent D, Moriou C, Al-Mourabit A. Org. Lett. 2009;11:4874–4877.

    1. Keifer PA, Koker MES, Schwartz RE, Hughes RG, Jr., Rittschof D, Rinehart KL. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans. Sep. 28–Oct. 1, 1986; No. 1281.
    2. Rinehart KL. Pure Appl. Chem. 1989;6:525–528.
    3. Kobayashi J, Tsuda M, Murayama T, Nakamura H, Ohizumi Y, Ishibashi M, Iwamura M, Ohta T, Nozoe S. Tetrahedron. 1990;46:5579–5586.
    4. Keifer PA, Schwartz RE, Koker MES, Hughes RG, Rittschof D, Rinehart KL. J. Org. Chem. 1991;56:2965–2975.
    5. Williams DH, Faulkner DJ. Tetrahedron. 1996;52:5381–5390.
    1. Nishimura S, Matsunaga S, Shibazaki M, Suzuki K, Furihata K, van Soest RWM, Fusetani N. Org. Lett. 2003;5:2255–2257. - PubMed

Publication types